Monitoring of Antiretroviral Therapy and Mortality in HIV Programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study

Objectives Mortality in patients starting antiretroviral therapy (ART) is higher in Malawi and Zambia than in South Africa. We examined whether different monitoring of ART (viral load [VL] in South Africa and CD4 count in Malawi and Zambia) could explain this mortality difference. Design: Mathematical modelling study based on data from ART programmes. Methods We used a stochastic simulation model to study the effect of VL monitoring on mortality over 5 years. In baseline scenario A all parameters were identical between strategies except for more timely and complete detection of treatment failure with VL monitoring. Additional scenarios introduced delays in switching to second-line ART (scenario B) or higher virologic failure rates (due to worse adherence) when monitoring was based on CD4 counts only (scenario C). Results are presented as relative risks (RR) with 95% prediction intervals and percent of observed mortality difference explained. Results RRs comparing VL with CD4 cell count monitoring were 0.94 (0.74–1.03) in scenario A, 0.94 (0.77–1.02) with delayed switching (scenario B) and 0.80 (0.44–1.07) when assuming a 3-times higher rate of failure (scenario C). The observed mortality at 3 years was 10.9% in Malawi and Zambia and 8.6% in South Africa (absolute difference 2.3%). The percentage of the mortality difference explained by VL monitoring ranged from 4% (scenario A) to 32% (scenarios B and C combined, assuming a 3-times higher failure rate). Eleven percent was explained by non-HIV related mortality. Conclusions VL monitoring reduces mortality moderately when assuming improved adherence and decreased failure rates.

[1]  A. Wagstaff,et al.  A Cluster Randomized Trial , 2014 .

[2]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[3]  Thomas Gsponer,et al.  Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis , 2012, AIDS.

[4]  Richard Degerman,et al.  Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial , 2011, BMJ : British Medical Journal.

[5]  E. Delaporte,et al.  Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. , 2011, The Lancet. Infectious diseases.

[6]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[7]  T. F. Rinke de Wit,et al.  Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.

[8]  M. Egger,et al.  Correcting Mortality for Loss to Follow-Up: A Nomogram Applied to Antiretroviral Treatment Programmes in Sub-Saharan Africa , 2011, PLoS medicine.

[9]  HIV treatment reaching 6.6 million people, but majority still in need: WHO embarks on a new HIV strategy to boost further progress in 2011-2015. , 2011, Central European Journal of Public Health.

[10]  M. Weinstein,et al.  Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness , 2010, Journal of acquired immune deficiency syndromes.

[11]  I. Sanne,et al.  Using vital registration data to update mortality among patients lost to follow‐up from ART programmes: evidence from the Themba Lethu Clinic, South Africa , 2010, Tropical medicine & international health : TM & IH.

[12]  B. Chi,et al.  A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics , 2010, PloS one.

[13]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[14]  N. Ford,et al.  Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa , 2010, AIDS.

[15]  J. Nachega,et al.  Evaluation of Paradoxical TB-Associated IRIS With the Use of Standardized Case Definitions For Resource-Limited Settings , 2010, Journal of the International Association of Physicians in AIDS Care.

[16]  M. Egger,et al.  Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy , 2009, Tropical medicine & international health : TM & IH.

[17]  M. Egger,et al.  Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring , 2009, AIDS.

[18]  J. Hogan,et al.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Egger,et al.  Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings: Systematic Review and Meta-Analysis , 2009, PloS one.

[20]  M. Peeters,et al.  Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Jahn,et al.  Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi , 2009, Tropical doctor.

[22]  Organización Mundial de la Salud,et al.  Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .

[23]  Mark J van der Laan,et al.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification , 2008, AIDS.

[24]  P. Mee,et al.  Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa , 2008, AIDS.

[25]  M. Egger,et al.  Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared , 2008, PLoS medicine.

[26]  Deenan Pillay,et al.  Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model , 2008, The Lancet.

[27]  Summary TOWARDS UNIVERSAL ACCESS : Scaling up Priority HIV / AIDS Interventions in the Health Sector Progress Report , 2008 .

[28]  F. Maggiolo,et al.  Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients , 2007, HIV clinical trials.

[29]  S. Lawn,et al.  Conservation of First-Line Antiretroviral Treatment Regimen where Therapeutic Options are Limited , 2007, Antiviral therapy.

[30]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[31]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[32]  L. Myer,et al.  Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design , 2005, AIDS.

[33]  S. Hammer,et al.  Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. , 2000, Archives of internal medicine.